Literature DB >> 16701508

Effects of Clostridium perfringens phospholipase C in mammalian cells.

Marietta Flores-Díaz1, Monica Thelestam, Graeme C Clark, Richard W Titball, Alberto Alape-Girón.   

Abstract

Clostridium perfringens phospholipase C (Cp-PLC), the major virulence factor in the pathogenesis of gas gangrene, is a Zn(2+) metalloenzyme with lecithinase and sphingomyelinase activities. Its structure shows an N-terminal domain containing the active site, and a C-terminal Ca(2+) binding domain required for membrane interaction. Although the knowledge of the structure of Cp-PLC and its interaction with aggregated phospholipids has advanced significantly, an understanding of the effects of Cp-PLC in mammalian cells is still incomplete. Cp-PLC binds to artificial bilayers containing cholesterol and sphingomyelin or phosphatidylcholine (PC) and degrades them, but glycoconjugates present in biological membranes influence its binding or positioning toward its substrates. Studies with Cp-PLC variants harboring single amino-acid substitutions have revealed that the active site, the Ca(2+) binding region, and the membrane interacting surface are required for cytotoxic and haemolytic activity. Cp-PLC causes plasma membrane disruption at high concentrations, whereas at low concentrations it perturbs phospholipid metabolism, induces DAG generation, PKC activation, Ca(2+) mobilization, and activates arachidonic acid metabolism. The cellular susceptibility to Cp-PLC depends on the composition of the plasma membrane and the capacity to up-regulate PC synthesis. The composition of the plasma membrane determines whether Cp-PLC can bind and acquire its active conformation, and thus the extent of phospholipid degradation. The capacity of PC synthesis and the availability of precursors determine whether the cell can replace the degraded phospholipids. Whether the perturbations of signal transduction processes caused by Cp-PLC play a role in cytotoxicity is not clear. However, these perturbations in endothelial cells, platelets and neutrophils lead to the uncontrolled production of intercellular mediators and adhesion molecules, which inhibits bacterial clearance and induces thrombotic events, thus favouring bacterial growth and spread in the host tissues.

Entities:  

Year:  2004        PMID: 16701508     DOI: 10.1016/j.anaerobe.2003.11.002

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  5 in total

1.  Ceramide-enriched membrane domains in red blood cells and the mechanism of sphingomyelinase-induced hot-cold hemolysis.

Authors:  L-Ruth Montes; David J López; Jesús Sot; Luis A Bagatolli; Martin J Stonehouse; Michael L Vasil; Bill X Wu; Yusuf A Hannun; Félix M Goñi; Alicia Alonso
Journal:  Biochemistry       Date:  2008-10-01       Impact factor: 3.162

2.  Sphingomyelinase activity of Trichomonas vaginalis extract and subfractions.

Authors:  Francisco González-Salazar; Jesús N Garza-González; Carlos E Hernandez-Luna; Benito David Mata-Cárdenas; Pilar Carranza-Rosales; Jorge Enrique Castro-Garza; Magda Elizabeth Hernández-García; Javier Vargas-Villarreal
Journal:  Biomed Res Int       Date:  2013-08-19       Impact factor: 3.411

3.  Clostridium perfringens α-toxin impairs erythropoiesis by inhibition of erythroid differentiation.

Authors:  Teruhisa Takagishi; Masaya Takehara; Soshi Seike; Kazuaki Miyamoto; Keiko Kobayashi; Masahiro Nagahama
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

Review 4.  Mechanisms of Action and Cell Death Associated with Clostridium perfringens Toxins.

Authors:  Mauricio A Navarro; Bruce A McClane; Francisco A Uzal
Journal:  Toxins (Basel)       Date:  2018-05-22       Impact factor: 4.546

5.  Clostridium perfringens phospholipase C induced ROS production and cytotoxicity require PKC, MEK1 and NFκB activation.

Authors:  Laura Monturiol-Gross; Marietta Flores-Díaz; Maria Jose Pineda-Padilla; Ana Cristina Castro-Castro; Alberto Alape-Giron
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.